LUXEMBOURG, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider and marketplace for the real estate and mortgage industries, filed a Form S-3 Registration Statement with the Securities and Exchange Commission on October 24, 2025 related to the registration of the resale of the shares previously issued to its lenders under the Securities Act of 1933, as amended (the “Form S-3”). On February 19, 2025, Altisource entered into ...

Core Insights - KellyOCG has been recognized as a Leader in Everest Group's 2025 PEAK Matrix for both Contingent Workforce Management (CWM) / Managed Service Provider (MSP) and Services Procurement / Statement of Work (SOW), and has also been named a Star Performer in the SOW category [1][3] Company Developments - KellyOCG has made significant investments in contingent workforce management and services procurement solutions following its acquisition of Motion Recruitment Partners, integrating resources from KellyOCG and Kelly Professional & Industrial with capabilities from Sevenstep into a new Enterprise Talent Management function [2][3] - The company has strengthened its presence in the CWM market through its Enterprise Talent Management model and the acquisition of Motion Recruitment Partners, including Sevenstep [3] Technology and Innovation - KellyOCG's technology stack provides detailed analytics, actionable insights, and streamlined access to talent, suppliers, and services, which gives clients a competitive advantage in the talent market [2] - The company is enhancing its SOW capabilities with a modular framework that integrates Helix UX, Helix Analytics, Globality, and TDX to deliver end-to-end sourcing, compliance, and supplier visibility [3] Market Assessment - Everest Group's PEAK Matrix provides an objective, data-driven assessment of global CWM/MSP and SOW providers based on their market impact, vision, and capability, with providers ranked as Leaders, Major Contenders, or Aspirants [3]

HALIFAX, Nova Scotia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Morien Resources Corp. (“Morien” or the “Company”) (TSX-V: MOX) is pleased to announce the identification and advancement of the Lazy Head Aggregate Project (“Lazy Head” or the “Project”) in the Municipality District of Guysborough (the “MODG”), Nova Scotia – the first project to emerge from Morien’s strategic partnership with Carver Companies, LLC (“Carver”), a private U.S. based producer and distributor of construction aggregates. Lazy Head contempla ...

GARDENA, CA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power”) (NASDAQ: POLA), a manufacturer of DC generators, battery charging systems, EV chargers, microgrids, and backup power solutions, today announced it has received a $674,000 contract from a military customer for the delivery of compact, lightweight DC generators designed for mobile applications. The newly proposed model is approximately 25% smaller and lighter than Polar Power’s smallest generator currently deployed in military an ...

Core Insights - Ayurcann Holdings Corp. has reported strong financial and operational results for the fiscal year ended June 30, 2025, highlighting its growth and market position in the Canadian cannabis industry [1][5]. Financial Highlights - Gross revenue reached CAD 55,446,352 for the fiscal year 2025, an increase from CAD 45,265,235 in 2024, reflecting a significant year-over-year growth [8]. - Adjusted EBITDA improved to CAD 507,570, compared to a loss of CAD 352,492 in FY2024, indicating a turnaround in financial performance [8]. Operational Highlights - The product portfolio has expanded to 80 SKUs nationwide, demonstrating the company's commitment to innovation and product diversity [8][9]. - Ayurcann's products are available in over 75% of licensed retail cannabis stores across Canada, showcasing a robust national distribution network [3]. - In Ontario, the largest cannabis market in Canada, Ayurcann has achieved over 80% retail penetration, with products in more than 1,500 licensed stores [4]. Market Position - Ayurcann has maintained a 100% year-over-year sales growth for the past three fiscal years (2021-2024), underscoring its operational strength and market leadership [2]. - The company has established strong relationships with the Ontario Cannabis Store and retail partners, enabling it to capture significant market share [4]. Corporate Update - Ayurcann will voluntarily delist from the OTCQB effective October 30, 2025, while continuing to trade on the Canadian Securities Exchange under the ticker symbol "AYUR" [10].

Core Insights - Repligen Corporation reported strong financial results for Q3 2025, achieving 18% organic growth and a total revenue of $189 million, representing a 22% year-over-year increase [2][5][7] - The company raised its full-year revenue guidance to a range of $729 million to $737 million, indicating a projected non-COVID organic growth of 14% to 15.5% [3][5][10] Financial Performance - Q3 2025 revenue was $189 million, up from $155 million in Q3 2024, with a year-over-year increase of 22% as reported and 18% organic [5][7] - Year-to-date revenue for 2025 reached $540 million compared to $467 million for the same period in 2024 [7] - GAAP net income for Q3 2025 was $15 million, compared to a loss of $1 million in Q3 2024, with adjusted net income at $26 million versus $24 million [7][24] Growth Drivers - All franchises experienced double-digit revenue growth, with consumables and capital equipment revenues growing over 20% [6][5] - The Asia Pacific region led geographical growth, also exceeding double digits [6] - The launch of SoloVPE® PLUS contributed to record placements in Process Analytics equipment [6] Financial Guidance - The updated guidance for FY 2025 includes total reported revenue of $729 million to $737 million, with an expected growth rate of 15% to 16% [10] - Adjusted net income guidance is set between $93.5 million and $95 million, with diluted earnings per share projected at $1.65 to $1.68 [10][34] Margin Analysis - Q3 2025 GAAP gross margin improved to 53.2% from 50.0% in Q3 2024, while adjusted gross margin was 53.3% compared to 50.7% [8][29] - Operating margin for Q3 2025 was 8.9%, a significant improvement from a loss margin of (5.1)% in Q3 2024 [8][29] Strategic Initiatives - Repligen announced a strategic partnership with Novasign to integrate digital twin capabilities into its filtration systems [6] - The company continues to focus on innovation and efficiency in bioprocessing technologies, serving biopharmaceutical developers and CDMOs globally [13]

Charlotte, NC, Oct. 28, 2025 (GLOBE NEWSWIRE) -- FG Nexus (Nasdaq: FGNX, FGNXP) (the "Company" or "FG Nexus"), today announced that management will participate at the ThinkEquity Conference on October 30th, 2025 at the Mandarin Oriental Hotel in New York City. Management will deliver a presentation on FG Nexus’ ETH treasury strategy and the Company’s views of Ethereum’s long-term impact on global financial markets. They will also be available for one-on-one meetings during the conference. Investors may regi ...

Core Insights - Midland Exploration Inc. announced positive gold results from its Caniapisc Au project, indicating a successful follow-up exploration program that identified new gold-bearing boulders and significant assay values [1][3][4] Exploration Program Details - The autumn exploration program included geological mapping, prospecting, soil sampling, and a 2,001-kilometre magnetic and electromagnetic geophysical survey [3][4][9] - A total of 111 grab rock samples and 112 soil samples were collected during the follow-up campaign, with results for soil samples still pending [3][5] Key Findings - The exploration program identified several new gold-bearing boulders, with a maximum assay value of 24.5 g/t Au from a selected grab sample [4][8] - Out of the rock samples, 16 returned gold values exceeding 0.5 g/t, including eight samples greater than 2.0 g/t Au [4][5] - A specific boulder returned a value of 19.2 g/t Au, while another returned 11.9 g/t Au, indicating a promising mineralization potential in the area [8] Geological Context - The Caniapisc Au project is located within the Ashuanipi Subprovince, characterized by a volcanosedimentary belt with historical exploration highlighting the potential for various mineralizations [10] - Previous till sampling surveys in the area identified gold anomalies, suggesting further exploration opportunities [10] Quality Control Measures - Rock and soil samples were analyzed at Actlabs laboratories, employing industry-standard quality assurance and control practices [12]

Limited-Edition Spinach® Green Apple-Flavored Limited-Edition Spinach® Green Apple-Flavored TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, announced today that it is welcoming back its limited-edition Caramel Green Apple flavor to its best-selling lineup of SOURZ by Spinach® edibles for the fall and Halloween season. The return of this popular and limited-edition product, which features buttery, sweet carame ...

Core Insights - Kiniksa Pharmaceuticals reported a significant increase in net product revenue for ARCALYST, reaching $180.9 million in Q3 2025, which represents a 61% year-over-year growth [1][7] - The company raised its 2025 net sales guidance for ARCALYST to between $670 million and $675 million, up from a previous estimate of $625 million to $640 million [2][13] - KPL-387 received Orphan Drug Designation from the FDA for the treatment of pericarditis, indicating potential for expanded treatment options in this area [1][15] Financial Results - Total revenue for Q3 2025 was $180.9 million, compared to $112.2 million in Q3 2024 [7][22] - Net income for Q3 2025 was $18.4 million, a turnaround from a net loss of $12.7 million in Q3 2024 [13][22] - Cash balance increased by $44.3 million in Q3 2025, totaling $352.1 million as of September 30, 2025 [1][13] Portfolio Execution - The average total duration of ARCALYST therapy for recurrent pericarditis increased to approximately 32 months by the end of Q3 2025, up from 27 months at the end of 2024 [7] - Kiniksa is on track to report data from the Phase 2 dose-focusing portion of the KPL-387 Phase 2/3 trial in the second half of 2026 [2][7] - KPL-1161 is undergoing IND-enabling development activities, targeting quarterly subcutaneous dosing [5][16] Market Position - Over 3,825 prescribers have written ARCALYST prescriptions for recurrent pericarditis since its launch, indicating strong market adoption [7] - The company aims to enhance its IL-1α & IL-1β inhibition franchise with the development of KPL-387, potentially expanding its market penetration [2][15]